Terms: = Pancreatic cancer AND PR, PGR, progesterone receptor AND Treatment
260 results:
1. Surgical treatment improves overall survival of hepatocellular carcinoma with extrahepatic metastases after conversion therapy: a multicenter retrospective study.
Zhang X; Zhu X; Zhong J; Zhao Y; Zhang X; Zhang W; Ye F; Yang C; Xue J; Xiong R; Wang J; Shen S; Pan Y; Li D; Song T; Bi X; Sun H; Xiang B; Gu S; Wen T; Lu S; Chen Y; Yin T; Liu L; Kuang M; Xu L; Li D; Cai J
Sci Rep; 2024 Apr; 14(1):9745. PubMed ID: 38679630
[TBL] [Abstract] [Full Text] [Related]
2. Value of diffusion kurtosis MR imaging and conventional diffusion weighed imaging for evaluating response to first-line chemotherapy in unresectable pancreatic cancer.
Zhang Z; Zhang Y; Hu F; Xie T; Liu W; Xiang H; Li X; Chen L; Zhou Z
Cancer Imaging; 2024 Feb; 24(1):29. PubMed ID: 38409049
[TBL] [Abstract] [Full Text] [Related]
3. Outcomes of Salvage Surgery Versus Non-Salvage Surgery for Initially Unresectable Hepatocellular Carcinoma After Conversion Therapy with Transcatheter Arterial Chemoembolization Combined with Lenvatinib Plus Anti-PD-1 Antibody: A Multicenter Retrospective Study.
Wu JY; Wu JY; Fu YK; Ou XY; Li SQ; Zhang ZB; Zhou JY; Li B; Wang SJ; Chen YF; Yan ML
Ann Surg Oncol; 2024 May; 31(5):3073-3083. PubMed ID: 38316732
[TBL] [Abstract] [Full Text] [Related]
4. Making "cold" tumors "hot"- radiotherapy remodels the tumor immune microenvironment of pancreatic cancer to benefit from immunotherapy: a case report.
Tong F; Sun Y; Zhu Y; Sha H; Ni J; Qi L; Gu Q; Zhu C; Xi W; Liu B; Kong W; Du J
Front Immunol; 2023; 14():1277810. PubMed ID: 38179049
[TBL] [Abstract] [Full Text] [Related]
5. ABCB1 overexpression through locus amplification represents an actionable target to combat paclitaxel resistance in pancreatic cancer cells.
Bergonzini C; Gregori A; Hagens TMS; van der Noord VE; van de Water B; Zweemer AJM; Coban B; Capula M; Mantini G; Botto A; Finamore F; Garajova I; McDonnell LA; Schmidt T; Giovannetti E; Danen EHJ
J Exp Clin Cancer Res; 2024 Jan; 43(1):4. PubMed ID: 38163893
[TBL] [Abstract] [Full Text] [Related]
6. Clinical Significance of Multi-cancer Genome Profiling: Data from a Single Hospital in Japan.
Aoyama R; Nishikubo H; Kawabata K; Kanei S; Yamamoto Y; Nishimura S; Yashiro M
Cancer Genomics Proteomics; 2024; 21(1):79-87. PubMed ID: 38151295
[TBL] [Abstract] [Full Text] [Related]
7. Actinomycin D synergizes with Doxorubicin in triple-negative breast cancer by inducing P53-dependent cell apoptosis.
Yang H; Li S; Li W; Yang Y; Zhang Y; Zhang S; Hao Y; Cao W; Xu F; Wang H; Du G; Wang J
Carcinogenesis; 2024 Apr; 45(4):262-273. PubMed ID: 37997385
[TBL] [Abstract] [Full Text] [Related]
8. Differential Sensitivity to Ionizing Radiation in Gemcitabine-Resistant and Paclitaxel-Resistant pancreatic cancer Cells.
Che PP; Gregori A; Bergonzini C; Ali M; Mantini G; Schmidt T; Finamore F; Rodrigues SMF; Frampton AE; McDonnell LA; Danen EH; Slotman BJ; Sminia P; Giovannetti E
Int J Radiat Oncol Biol Phys; 2024 Apr; 118(5):1328-1343. PubMed ID: 37914140
[TBL] [Abstract] [Full Text] [Related]
9. Association between BRCA Gene Variants and the Response to Modified FOLFIRINOX in Patients with Unresectable pancreatic cancer.
Horiguchi S; Matsumoto K; Morimoto K; Matsumi A; Terasawa H; Fujii Y; Yamazaki T; Tsutsumi K; Kato H
Acta Med Okayama; 2023 Oct; 77(5):517-525. PubMed ID: 37899263
[TBL] [Abstract] [Full Text] [Related]
10. Effectiveness and safety of human type 5 recombinant adenovirus (H101) in malignant tumor with malignant pleural effusion and ascites: A multicenter, observational, real-world study.
Wang B; Zhong C; Liao Z; Wang H; Cai X; Zhang Y; Wang J; Wang T; Yao H
Thorac Cancer; 2023 Oct; 14(30):3051-3057. PubMed ID: 37675621
[TBL] [Abstract] [Full Text] [Related]
11. Gemcitabine, Docetaxel, Capecitabine, Cisplatin, Irinotecan as First-line treatment for Metastatic pancreatic cancer.
Wilbur HC; Durham JN; Lim SJ; Purtell K; Bever KM; Laheru DA; De Jesus-Acosta A; Azad NS; Wilt B; Diaz LA; Le DT; Wang H
Cancer Res Commun; 2023 Aug; 3(8):1672-1677. PubMed ID: 37645623
[TBL] [Abstract] [Full Text] [Related]
12. Pathologic tumor response to neoadjuvant therapy in resected pancreatic cancer: does it affect prognosis?
Donisi G; Nappo G; Pacilli M; Capretti GL; Spaggiari P; Sollai M; Bozzarelli S; Zerbi A
Updates Surg; 2023 Sep; 75(6):1497-1508. PubMed ID: 37578734
[TBL] [Abstract] [Full Text] [Related]
13. Stent Graft of Pseudoaneurysm Rupture After Subtotal Stomach-preserving pancreaticoduodenectomy.
Kimura K; Minagawa R; Yamaoka T; Izumi T; Takahashi YU; Nakanishi M; Tokunaga T; Matsuda D; Honma K; Nagata S; Minami K; Nishizaki T
Anticancer Res; 2023 Aug; 43(8):3639-3645. PubMed ID: 37500164
[TBL] [Abstract] [Full Text] [Related]
14. A comprehensive analysis of tumor-stromal collagen in relation to pathological, molecular, and immune characteristics and patient survival in pancreatic ductal adenocarcinoma.
Ashina S; Masuda A; Yamakawa K; Hamada T; Tsujimae M; Tanaka T; Toyama H; Sofue K; Shiomi H; Sakai A; Kobayashi T; Abe S; Gonda M; Masuda S; Inomata N; Uemura H; Kohashi S; Nagao K; Harada Y; Miki M; Juri N; Irie Y; Kanzawa M; Itoh T; Inoue J; Imai T; Fukumoto T; Kodama Y
J Gastroenterol; 2023 Oct; 58(10):1055-1067. PubMed ID: 37477731
[TBL] [Abstract] [Full Text] [Related]
15. Combination of pembrolizumab and pelareorep promotes anti-tumour immunity in advanced pancreatic adenocarcinoma (PDAC).
Mahalingam D; Chen S; Xie P; Loghmani H; Heineman T; Kalyan A; Kircher S; Helenowski IB; Mi X; Maurer V; Coffey M; Mulcahy M; Benson A; Zhang B
Br J Cancer; 2023 Sep; 129(5):782-790. PubMed ID: 37443348
[TBL] [Abstract] [Full Text] [Related]
16. Malignancy risk factors and prognostic variables of pancreatic mucinous cystic neoplasms in Chinese patients.
Xia Q; Li F; Min R; Sun S; Han YX; Feng ZZ; Li N
World J Gastroenterol; 2023 May; 29(20):3119-3132. PubMed ID: 37346158
[TBL] [Abstract] [Full Text] [Related]
17. Calcium electroporation in cutaneous metastases - A non-randomised phase II multicentre clinical trial.
Vissing M; Pervan M; Pløen J; Schnefeldt M; Rafaelsen SR; Jensen LH; Rody A; Gehl J
Eur J Surg Oncol; 2023 Sep; 49(9):106925. PubMed ID: 37268521
[TBL] [Abstract] [Full Text] [Related]
18. MGMT is frequently inactivated in pancreatic NET-G2 and is associated with the therapeutic activity of STZ-based regimens.
Yagi K; Ono H; Kudo A; Kinowaki Y; Asano D; Watanabe S; Ishikawa Y; Ueda H; Akahoshi K; Tanaka S; Tanabe M
Sci Rep; 2023 May; 13(1):7535. PubMed ID: 37161026
[TBL] [Abstract] [Full Text] [Related]
19. First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors.
Bendell J; LoRusso P; Overman M; Noonan AM; Kim DW; Strickler JH; Kim SW; Clarke S; George TJ; Grimison PS; Barve M; Amin M; Desai J; Wise-Draper T; Eck S; Jiang Y; Khan AA; Wu Y; Martin P; Cooper ZA; Elgeioushi N; Mueller N; Kumar R; Patel SP
Cancer Immunol Immunother; 2023 Jul; 72(7):2443-2458. PubMed ID: 37016126
[TBL] [Abstract] [Full Text] [Related]
20. cancer-cell-derived sialylated IgG as a novel biomarker for predicting poor pathological response to neoadjuvant therapy and prognosis in pancreatic cancer.
Cui M; Shoucair S; Liao Q; Qiu X; Kinny-Köster B; Habib JR; Ghabi EM; Wang J; Shin EJ; Leng SX; Ali SZ; Thompson ED; Zimmerman JW; Shubert CR; Lafaro KJ; Burkhart RA; Burns WR; Zheng L; He J; Zhao Y; Wolfgang CL; Yu J
Int J Surg; 2023 Feb; 109(2):99-106. PubMed ID: 36799816
[TBL] [Abstract] [Full Text] [Related]
[Next]
